for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Viking Therapeutics Inc

VKTX.OQ

Latest Trade

6.85USD

Change

-0.42(-5.78%)

Volume

3,557,954

Today's Range

6.58

 - 

7.35

52 Week Range

6.53

 - 

20.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.27
Open
7.26
Volume
3,557,954
3M AVG Volume
26.55
Today's High
7.35
Today's Low
6.58
52 Week High
20.84
52 Week Low
6.53
Shares Out (MIL)
72.21
Market Cap (MIL)
524.97
Forward P/E
-15.15
Dividend (Yield %)
--

Next Event

Viking Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Viking Therapeutics Inc - On August 1, Entered Into An At-Market Equity Offering Sales Agreement

Viking Therapeutics Posts Q2 LOSS PER SHARE Of $0.11

Viking Therapeutics Q1 Loss Per Share $0.07

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Viking Therapeutics Inc

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Industry

Biotechnology & Drugs

Contact Info

12340 El Camino Real Ste 250

+1.858.7044660

http://www.vikingtherapeutics.com

Executive Leadership

Lawson Macartney

Independent Chairman of the Board

Brian W. Lian

President, Chief Executive Officer, Director

Michael Morneau

Vice President - Finance and Administration

Hiroko Masamune

Chief Development Officer

Matthew W. Foehr

Director

Key Stats

1.55 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.900

2017

-0.790

2018

-0.380

2019(E)

-0.476
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-11.39
Return on Equity (TTM)
-11.13

Latest News

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

Viking Therapeutics liver drug succeeds in mid-stage study

Viking Therapeutics Inc said on Tuesday its experimental liver disease treatment met the main goals of a mid-stage trial by reducing cholesterol and liver fat in patients.

BRIEF-Viking Therapeutics Q1 Loss Per Share $0.08

* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Viking Therapeutics Q4 Loss Per Share $0.14

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Viking Therapeutics - Pricing Public Offering Of 11 Mln Shares At $5 Per Share

* VIKING THERAPEUTICS ANNOUNCES PRICING OF $55.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sphera Funds Management Ltd Reports 7.43 Pct Passive Stake In Viking Therapeutics

* SPHERA FUNDS MANAGEMENT LTD REPORTS 7.43 PERCENT PASSIVE STAKE IN VIKING THERAPEUTICS INC AS OF DECEMBER 7 - SEC FILING Source text : http://bit.ly/2kdgndu Further company coverage:

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

BRIEF-Viking Therapeutics reports third quarter 2017 financial results

* Viking Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder

* Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc - SEC filing Source text: (http://bit.ly/2x3eVPr) Further company coverage:

BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214

* VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214 IN IN VIVO MODEL OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)

BRIEF-VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

* VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

BRIEF-Viking Therapeutics Q2 loss per share $0.21

* Viking Therapeutics reports second quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics completes enrollment in Phase 2 study of VK5211

* Viking Therapeutics completes enrollment in Phase 2 study of VK5211 in patients recovering from hip fracture

BRIEF-Viking therapeutics appoints Charles A. Rowland Jr. to board

* Viking Therapeutics appoints Charles A. Rowland Jr. to board of directors Source text for Eikon: Further company coverage:

BRIEF-Viking Therapeutics announces $4.3 mln registered direct offering

* Viking Therapeutics announces $4.3 million registered direct offering

BRIEF-Viking Therapeutics reports Q1 loss per share $0.23

* Viking Therapeutics reports first quarter 2017 financial results and provides corporate update

BRIEF-Viking Therapeutics Q4 loss per share $0.18

* Viking therapeutics reports fourth quarter and year-end 2016 financial results and provides corporate update

BRIEF-POC Capital reports 5.7 pct stake in Viking Therapeutics

* POC Capital Llc reports 5.7 percent stake in Viking Therapeutics Inc as of February 8, 2017 - sec filing Source text- http://bit.ly/2lstQjy Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up